Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 7

1.

Human tissue distribution of voriconazole.

Weiler S, Fiegl D, MacFarland R, Stienecke E, Bellmann-Weiler R, Dunzendorfer S, Joannidis M, Bellmann R.

Antimicrob Agents Chemother. 2011 Feb;55(2):925-8. doi: 10.1128/AAC.00949-10. Epub 2010 Nov 15.

2.

Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis.

Howard A, Hoffman J, Sheth A.

Ann Pharmacother. 2008 Dec;42(12):1859-64. doi: 10.1345/aph.1L243. Epub 2008 Nov 18. Review.

PMID:
19017830
3.

Clinical pharmacokinetics of voriconazole.

Levêque D, Nivoix Y, Jehl F, Herbrecht R.

Int J Antimicrob Agents. 2006 Apr;27(4):274-84. Epub 2006 Mar 24. Review.

PMID:
16563707
4.

Treatment of refractory cerebral aspergillosis in a liver transplant recipient with voriconazole: case report and review of the literature.

Cherian T, Giakoustidis A, Yokoyama S, Heneghan M, O'Grady J, Rela M, Wendon J, Heaton DN, Verma A.

Exp Clin Transplant. 2012 Oct;10(5):482-6. Review.

5.

[Level of evidence for therapeutic drug monitoring of voriconazole].

Hulin A, Dailly E, Le Guellec C; Groupe Suivi Therapeutique Pharmacologique de la Societe Francaise de Pharmacologie et de Therapeutique.

Therapie. 2011 Mar-Apr;66(2):109-14. Epub 2011 Jun 6. Review. French.

PMID:
21635857
6.

[Voriconazole: a new weapon against invasive fungal infections].

Aoun M.

Rev Med Brux. 2004 Jun;25(3):166-71. Review. French.

PMID:
15291449
7.

Voriconazole: in the treatment of invasive aspergillosis.

Muijsers RB, Goa KL, Scott LJ.

Drugs. 2002;62(18):2655-64; discussion 2665-6. Review.

PMID:
12466006

Supplemental Content

Support Center